Sanofi : A risk/reward profile on the pipeline that remains attractive
>Tolebrutinib reassures the market - The positive top line results from the HERCULES study (non-active secondary progressive MS) have helped to reassure the market on the ambitions for tolebrutinib. The failure of the GEMINI 1 & 2 studies should prompt Sanofi to fine-tune its guidance for peak sales for this drug in the coming months. Initially anticipated at between € 2bn and € 5bn, all indications included, this should be adjusted to between € 1.5bn and € 3bn depen...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.